title: Rituximab for systemic sclerosis: arrest of pulmonary disease progression in five cases. Results of a lower dosage and shorter interval regimen.
authors.affiliation: Division of Rheumatology and Immunology, Medical University of Graz , Austria.
authors.forename: F C
authors.initials: FC
authors.lastname: Moazedi-Fuerst
authors.forename: S M
authors.initials: SM
authors.lastname: Kielhauser
authors.forename: K
authors.initials: K
authors.lastname: Brickmann
authors.forename: J
authors.initials: J
authors.lastname: Hermann
authors.forename: A
authors.initials: A
authors.lastname: Lutfi
authors.forename: M
authors.initials: M
authors.lastname: Meilinger
authors.forename: H P
authors.initials: HP
authors.lastname: Brezinschek
authors.forename: W B
authors.initials: WB
authors.lastname: Graninger
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage* / Q000009:adverse effects; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D011658:Pulmonary Fibrosis / Q000188:drug therapy* / Q000209:etiology; D018570:Risk Assessment; D000069283:Rituximab; D012595:Scleroderma, Systemic / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab